Safety and Tolerability
Conditions
Brief summary
Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants
Detailed description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Interventions
DRUGExperimental drug: ESK-001
Multiple doses of ESK-001
OTHERPlacebo
Placebo
Sponsors
Alumis Inc
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit * Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters * Other inclusions as specified in the protocol
Exclusion criteria
* Participant has a prior exposure to ESK-001 * Participant has a history of hypersensitivity to any of the ingredients of ESK-001 * Other exclusions as specified in the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) | Up to 14 days | Safety and tolerability |
| Incidence of Serious Adverse Events (SAEs) | Up to 14 days | Safety and tolerability |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14. | Up to 14 days | Pharmacokinetics |
| The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14. | Up to 14 days | Pharmacokinetics |
| Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14 | Up to 14 days | Pharmacokinetics |
| The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14 | Up to 14 days | Pharmacokinetics |
| The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14 | Up to 14 days | Pharmacokinetics |
| The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14. | Up to 14 days | Pharmacokinetics |
| Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001 | 14 days after first dose | Pharmacodynamics |
| Apparent clearance CL(Clearance)/F for ESK001 on Day 1 | Up to 14 days | Pharmacokinetics |
| The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14 | Up to 14 days | Pharmacokinetics |
Countries
United States
Outcome results
None listed